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INTRODUCTION
Non-myeloablative allogeneic peripheral stem cell transplan-
tation (NST) is an emerging treatment modality for malignant
and nonmalignant hematologic disorders. Because of their
low toxicity, nonmyeloablative preparative regimens are being
explored in patients who are not eligible for conventional
hematopoietic stem cell transplantation owing to age or med-
ical contraindications (1-4). However, several problems need
to be resolved in this procedure.
Although antiviral prophylaxis has led to a significant reduc-
tion in early cytomegalovirus (CMV) disease after hematopoi-
etic stem cell transplantation (HSCT), CMV infection con-
tinues to be a major cause of morbidity and mortality in pa-
tients undergoing this procedure (5). Several studies have
found a high rate of CMV infection after non-myeloablative
stem cell transplantation (NST) (6-8). However, it is still con-
troversial whether non-myeloablative procedure increases the
risk of CMV infection after HSCT, since there have been few
studies comparing NST and conventional HSCT. Therefore,
we examined whether NST affected the outcomes of CMV
infection in patients undergoing allogeneic HSCT. The pri-
mary end point of this study was to compare the incidence of
CMV infection and disease between NST group and CBT
group. Secondly, we compared the time to first detection of
CMV antigenemia, initial and maximal CMV antigen values
and serial change of CMV antigen values after pre-emptive
therapy using ganciclovir between these two groups. 
MATERIALS AND METHODS
Patients
We retrospectively analyzed the medical records of 64 con-
secutively registered CMV-seropositive patients who had
undergone allogeneic HSCT from HLA-identical or one-locus
mismatched sibling at the Asan Medical Center between
July 1999 and July 2001. Forty patients underwent conven-
tional bone marrow transplantation (CBT group), whereas
24 patients underwent non-myeloablative peripheral stem
cell transplantation (NST group). Patient characteristics are
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The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral
Stem Cell Transplantation Compared with Conventional Bone Marrow
Transplantation
Non-myeloablative allogeneic peripheral stem cell transplantation (NST) is a novel
therapeutic strategy for patients with hematologic malignancies. Whether non-mye-
loablative transplants are associated with increased risk of cytomegalovirus (CMV)
infections is unknown. To clarify this issue, we compared the outcome of CMV infec-
tion following 24 allogeneic non-myeloablative peripheral blood stem cell transplants
and 40 conventional bone marrow transplants (CBT). The NST regimen consisted
of busulfan (4 mg/kg/day), fludarabine (30 mg/m
2) and anti-thymocyte globulin (10
mg/kg). Twelve patients (50%) in the NST group and 17 (43%) in the CBT group
developed positive antigenemia before day 100 (p=0.60). The time to the first appear-
ance of positive antigenemia was not different between these two groups (p=0.40),
and two groups showed similar initial and maximal antigenemia values (p=0.56 and
p=0.68, respectively). Only one case of CMV colitis developed in the CBT group
whereas CMV disease did not develop in the NST group. Although statistically in-
significant, the treatment response against CMV antigenemia using ganciclovir was
in favor of NST group. In conclusion, there was no difference in the risk of CMV in-
fection between NST group and CBT group. Further prospective and controlled
study is needed to clarify the impact of non-myeloablative procedure on the outcome
of CMV infection.
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shown in Table 1.
Transplantation procedures
The NST regimen consisted of busulfan (4 mg/kg/day p.o.
on days -7 to -6), fludarabine (30 mg/m2/day i.v. on days -7
to -2), and anti-thymocyte globulin (ATG: 10 mg/kg/day
for on days -5 to -2). Granulocyte colony-stimulating factor
(G-CSF)-mobilized peripheral stem cells from donors were
infused on day 0 and 1. In the CBT group, all patients received
Bu-Cy regimen (busulfan 4 mg/kg/day p.o. on days -7 to -4
and cyclophosphamide i.v. 60 mg/kg/day on days -3 to -2)
and received bone marrow stem cell from donors.
GVHD prophylaxis and treatment
All patients received prophylactic therapy with cyclosporine
alone or cyclosporine and methotrexate for graft-versus-host
disease (GVHD) prophylaxis. Cyclosporine 1.5 mg/kg was
given intravenously every 12 hr starting on day -1, then
switched to an oral dose of two times the intravenous dose
when oral intake became feasible. If there was no evidence
of GVHD, the cyclosporine dose was tapered by 10% each
month starting on day 60. Intravenous methotrexate was given
at a dose of 15 mg/m2 on day 1 and 10 mg/m2 on days 3, 6
and 11. Patients who developed grade II-IV acute GVHD
were treated with methylpredinisolone at 1-2 mg/kg/day.
Supportive care
All patients were treated as inpatients in private rooms.
Patients received antibacterial and antifungal prophylaxis with
oral ciprofloxacin at 1,000 mg/day and fluconazole 100 mg/day
until the absolute neutrophil count (ANC) was over 3,000/ L.
Prophylaxis against herpes simplex was performed with acy-
clovir 750 mg/m2 i.v. from days -7 to 14 and then switched
to an oral dose at 600 mg/day until the end of immunosup-
pressive therapy. Intravenous globulin 500 mg/kg was given
once every 2 weeks from day -7 until day 120, then monthly
until day 180.
CMV antigenemia assay
All patients were monitored for CMV infection using a
CMV pp 65 antigenemia assay once a week from day -7 until
day 100 after BMT. Patients with a positive antigenemia test
were monitored twice weekly. The CMV antigenemia assay
was performed according to the method described previously
(9). In brief, 2×105peripheral blood leukocytes were attached
to slides using a cytocentrifuge and fixed with formaldehyde.
The cells were sequentially incubated with Clonab CMV
monoclonal antibodies C10/11 (Biotest AG, Dreieich, Ger-
many). After incubation, the slides were washed with pho-
sphate buffered saline (PBS) and then stained using alkaline
phosphatase anti-alkaline phosphatase (APAAP) technique.
If the target antigen (CMV matrix protein pp 65) is present,
a red reaction product forms at leukocyte. Reading was done
under a microscope to search for red reaction-positive cells.
Records were reported as the number of pp 65-positive cells
per 2×105 cells examined.
Preemptive therapy
Ganciclovir treatment was started on the day of the first
positive antigenemia findings for all patients with positive
CMV antigenemia at an induction dose of 5 mg/kg intrave-
nously twice daily for 1 week. Maintenance gancicovir ther-
apy was continued until day 100 after transplantation with
doses of 5 mg/kg/day 5 to 6 days per week. 
A neutropenic episode was defined as a decrease of the ANC
to 1,000/ L for 2 consecutive days. If the ANC dropped below
1,000/ L for 3 consecutive days, G-CSF was administered.
If the ANC dropped below 500/ L for >2 consecutive days
in spite of therapy, treatment with ganciclovir was temporarily
NST (n=24) CBT (n=40) p value
Median age (yr) 42 (21-59) 29 (16-49) 0.002
Sex
Male 15 14
Female 9 26 0.118
Donor
Sibling 23 40
Unrelated donor 1 0 0.375
GVHD prophylaxis
CsA 20 19
CsA+MTX 4 21 0.007
Disease
AML 3 22
ALL 1 3
CML 1 11
MDS 2 3
Solid tumors 5 0
Others* 12 1
Table 1. Patient characteristics
GVHD, graft-versus-host disease; CsA, cyclosporin; mTX, methotrexate.
*Others included Non-Hodgkin’s lymphoma (n=6), Hodgkin’s disease
(n=3), multiple myeloma (n=3), paroxysmal nocturnal hemoglobinuria
(n=2) in NST group, and one case of non-Hodgkin’s lymphoma in CBT
group.
Ag, Antigen.
NST group CBT group p value
CMV Ag (+) 12/24 (50%) 17/40 (43%) 0.600
Day of 1st Ag  
detection (range)  41 (12-97) 47 (20-75) 0.407
Initial Ag value 4 (1-110) 4 (1-190) 0.563
Maximal Ag value 4 (1-110) 7 (1-190) 0.680
CMV disease 0 1
Table 2. The comparison of CMV infection between NST and
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discontinued until the ANC returned to a level 1,000/ L on
2 successive days.
Definition of CMV disease 
CMV pneumonia was diagnosed on the basis of signs and
symptoms compatible with a diagnosis of pneumonia (dys-
pnea, interstitial infiltrates on chest radiography) and a bron-
choalveolar lavage fluid or lung biopsy specimen positive for
CMV by culture or immunohistology. Diagnosis of CMV
colitis was based on gastrointestinal signs or symptoms and
histologic demonstration of CMV. 
Statistical Analysis
Time to the documentation of first positive CMV antigen-
emia was estimated by the Kaplan-Meier method and the
differences between 2 groups were compared using the log-
rank test. We accepted a level of p<0.05 as statistically signif-
icant. To compare the mean levels of CMV antigenemia, we
used a Mann-Whitney U test. The differences of treatment
response for positive CMV antigenemia were compared using
repeated ANOVA. We performed the analysis using the SPSS
statistical program for Windows version 10.0.
RESULTS
Transplant outcome
All patients achieved engraftment except 1 patient in the
NST group. The NST group (median 11days) showed faster
neutrophil engraftment than CBT group (median 14 days).
Seven (29%) in the NST group and 5 (12%) in the CBT group
developed acute GVHD III-IV. After a median follow-up of
575 days (range 44-1146) for surviving patients, 30 CBT
patients are alive with an actuarial survival of 75%. In NST,
8 patients are alive with a median follow up of 234 days (range
49-1106) with an actuarial survival of 33%. Of 10 deaths in
CBT and 16 deaths in NST, 6 were due to relapse or disease
progression. Of the remaining 20 patients, 5 died of acute
GVHD, 8 patients died of infection, one patient died of graft
failure.
Incidence and levels of CMV Antigenemia
In the NST group, 12 patients (50%) developed antigen-
emia at a median onset of 44 days (range 12-97). Seventeen
patients (43%) developed CMV antigenemia at a median onset
of 47 days (range 20-75) in the CBT group. The time to the
first appearance of positive antigenemia was not different be-
tween these two groups (p=0.40, Fig. 1). The median num-
ber of initial CMV antigen value of NST group was 4 (range
1-110) and that of CBT group was 4 (range 1-190). The medi-
an number of maximal CMV antigen of NST group was 8
(range 1-110) and that of CBT group was 7 (range 1-190).
There was no significant difference in the degree of initial and
maximal CMV antigen value between NST group and CBT
group (Fig. 2).
Serial CMV antigenemia values after pre-emptive therapy
using ganciclovir 
Of the 12 NST group patients who had CMV antigenemia,
9 patients received pre-emptive therapy using ganciclovir and
one patient developed neutropenia. In the CBT group, 14
patients received pre-emptive therapy and 3 patients developed
neutropenia. The serial antigen value declined to baseline with-
in 7 weeks in all of the patients undergoing pre-emptive thera-
py. The serial change of antigenemia values during pre-emptive
therapy using ganciclovir is shown in Fig. 3. Although statis-
tically insignificant, there was a trend for the treatment res-
ponse using ganciclovir in favor of NST group (p=0.168).
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Fig. 1. Probability of developing positive CMV antigenemia after
non-myeloablative and conventional transplantation shown by
Kaplan-Meier curves.
Fig. 2. The initial (1st Ag) and maximum (Max Ag) antigenemia
values, compared between non-myeloablative and conventional
transplantation procedures.
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CMV disease
Among the patients who received pre-emptive therapy, no
patient developed CMV disease in the NST group whereas
one patient developed CMV colitis in the CBT group. The
patient who had CMV colitis suffered from acute GVHD
before the onset of disease and she was treated with combi-
nation of ganciclovir and intravenous immunoglobulin. She
recovered from CMV colitis after 1 month of therapy.
DISCUSSION
Following conventional allogeneic hematopoietic stem cell
transplantation, all patients experience a period of profound
neutropenia and immunodeficiency that are responsible for
serious infection. Over the past years several groups have devel-
oped non-myeloablative regimens, allowing engraftment of
donor hematopoietic stem cells with lesser toxicity compared
with conventional HSCT. This reduced extrahematologic toxi-
city may lead to a reduction in infectious complication post
transplant. However, in earlier studies, it was reported that
the risk of CMV infection had been increased in patients un-
dergoing NST. One potential assumption is the possible delay
of immune reconstitution after NST. Since the NST regimen
is primarily based on the concept of intensifying immunosup-
pression to enhance engraftment of donor cells rather than
cytoreduction, it is likely that CMV infection will increase
during this procedure. 
Mohty et al. reported a high frequency of CMV infections
after NST using a regimen consisting of fludarabine, busul-
fan and ATG (6). A higher incidence of early and late CMV
infection was also observed after a conditioning regimen
with fludarabine, melphalan, and Campath 1H, a mono-
clonal anti-CD52 antibody (7). In all of these NST protocol,
anti-thymocyte globulin or CAMPATH 1H was used in the
conditioning regimens for promoting engraftment, which
may lead to delayed reconstitution of CMV-specific T cell
responses post transplant. On the other hand, Junghanss et
al. observed a trend toward less CMV infection and disease
after NST using low-dose TBI with fludarabine (10). Naka-
mura et al. also showed a reduced incidence of CMV reacti-
vation after conditioning with fludarabine and cyclophos-
phamide (11). Therefore, the risk of CMV infection appears
to be influenced by the agents used in the NST regimen. 
In a recent study of Fred Hutchison Cancer Center, com-
paring 56 recipients of an NST with 112 matched recipients
of a myeloablative transplant found a lower probability of
CMV antigenemia, viremia in the former group (12). They
reported a similar incidence of CMV disease between the two
groups and delayed onset of the disease in the NST group.
They assumed that host hematopoietic cells, especially T lym-
phocytes, are not immediately eradicated by NST regimen
if anti-lymphocyte antibody was not used; host T cells were
present in the peripheral blood for up to 6 months. In con-
trast, conventional myeloablative conditioning regimens lead
to early and complete disappearance of host hematopoiesis.
On the basis of these findings, it is conceivable that the pro-
longed presence of host immunity after NST may provide
some protection against early CMV infection as compared
with conventional myeloablative transplantation. 
We used anti-thymocyte globulin in NST group as a con-
ditioning regimen. However, there was no significant differ-
ence in the outcome of CMV infection between NST and CBT
group in our study. The frequency of CMV antigenemia, time
to the first appearance of positive antigenemia after HSCT,
initial and maximal CMV antigen values did not differ bet-
ween these two groups. Although statistically insignificant,
the treatment response against CMV infection was in favor
of NST group rather than CBT group. These results may be
explained in the following. 
Our study had some limitations. The patient number was
small and this study was a retrospective analysis. The main
shortcoming of our study is the differences in baseline patient
characteristics between the two transplant groups. Since NST
allografts are currently offered to patients who are poor can-
didates for conventional myeloablative therapies due to older
age or medical co-morbidity, we were unable to perform a well-
matched cohort study. Some variables that may influence the
outcomes of CMV infection favor the NST group; others favor
the CBT group. Age has been described as a risk factor for
CMV disease (13). Median age of NST group was much higher
than CBT group which may have influenced the rate of CMV
infection. In addition, in our study, acute GVHD was much
more frequent in the NST group. Acute GVHD is a well
known risk factor of CMV infection and CMV disease. So this
result may negatively impact the outcome of CMV infection
in NST group. In a recent study from Germany, the incidence
of CMV antigenemia and CMV-related interstitial pneumonia
was lower in alloPBSCT compared to BMT recipients; sug-
Fig. 3. Serial changes in antigenemia values in patients receiving
ganciclovir were compared between non-myeloablative and con-
ventional transplantation.
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gesting more rapid immune reconstitution following PBSCT
compared to BMT(14). All of the CBT group patients in our
study received bone marrow stem cells from donors whereas
NST group patients received peripheral blood stem cells, a
fact favoring the NST group. Some variables favor NST group
and others favor CBT group. Overall they may have resulted
in no difference for the risk of CMV infection between the
two group.
In conclusion, our study showed that a new approach NST
did not increase the risk of CMV infection and disease com-
pared with CBT. Besides, the treatment response against
CMV infection using ganciclovir seemed to be in favor of
NST. However, our study had limitation mentioned above.
Large, prospective and well controlled studies are needed to
clarify the impact of NST procedure on the outcome of CMV
infection.
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